Intellia Therapeutics, Inc
$11.52
$0.16 (+1.44%)
$11.43Day Range$11.75
Key Statistics
Market Cap
$1.59B
Shares Outstanding
140.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 6, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$11.46
Day High
$11.75
Day Low
$11.43
Volume
1.69M
VWAP
$11.58
Prev Close
$11.36
Transactions
--
Acc. Volume
--
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 2835377 employees40 ERIE STREET, CAMBRIDGE, MA, 02139857-285-6200IPO May 6, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001652130
- Composite FIGI
- BBG007KC7PB0
- Share Class FIGI
- BBG007KC7PC9
- Ticker Root
- NTLA
- SIC Code
- 2835
About Intellia Therapeutics, Inc (NTLA) Stock
Intellia Therapeutics, Inc (NTLA) closed the 2026-09-16 session at $11.52, up 1.44% versus the previous close (+0.16). The stock opened at $11.46 and traded between $11.43 and $11.75 during that session. Session trading volume was 1.7M shares. The volume-weighted average price (VWAP) is $11.58.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics, Inc has a market capitalization of $1.59 billion. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. NTLA is listed on the XNAS exchange. The company employs approximately 377 people. Intellia Therapeutics, Inc is headquartered in CAMBRIDGE, MA. The recorded listing date is 2016-05-06.
On this page you can find market NTLA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.